BROOKS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Brooks Laboratories Approves Fund Raise Of Up To 750 Million Rupees
Dec 11 (Reuters) - Brooks Laboratories Ltd BROO.NS:
APPROVES FUND RAISE OF UP TO 750 MILLION RUPEES
FUND RAISE THROUGH ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS
Source text: ID:nBSE5FqDbH
Further company coverage: BROO.NS
(([email protected];))
Dec 11 (Reuters) - Brooks Laboratories Ltd BROO.NS:
APPROVES FUND RAISE OF UP TO 750 MILLION RUPEES
FUND RAISE THROUGH ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS
Source text: ID:nBSE5FqDbH
Further company coverage: BROO.NS
(([email protected];))
Brooks Laboratories Approved Raising Of Funds
Jan 24 (Reuters) - Brooks Laboratories Ltd BROO.NS:
APPROVED RAISING OF FUNDS WORTH UP TO 490 MILLION RUPEES
Source text for Eikon: ID:nBSE9l2c3b
Further company coverage: BROO.NS
(([email protected];;))
Jan 24 (Reuters) - Brooks Laboratories Ltd BROO.NS:
APPROVED RAISING OF FUNDS WORTH UP TO 490 MILLION RUPEES
Source text for Eikon: ID:nBSE9l2c3b
Further company coverage: BROO.NS
(([email protected];;))
Brooks Laboratories To Consider Raising Of Funds
Jan 17 (Reuters) - Brooks Laboratories Ltd BROO.NS:
TO CONSIDER AND APPROVE RAISING OF FUNDS
Source text for Eikon: ID:nBSE7thrV1
Further company coverage: BROO.NS
(([email protected];;))
Jan 17 (Reuters) - Brooks Laboratories Ltd BROO.NS:
TO CONSIDER AND APPROVE RAISING OF FUNDS
Source text for Eikon: ID:nBSE7thrV1
Further company coverage: BROO.NS
(([email protected];;))
Brooks Laboratories To Consider And Approve Fund Raising Through Rights Issue
Jan 16 (Reuters) - Brooks Laboratories Ltd BROO.NS:
TO CONSIDER AND APPROVE FUND RAISING THROUGH RIGHTS ISSUE
Source text for Eikon: ID:nBSE2xgtyB
Further company coverage: BROO.NS
(([email protected];))
Jan 16 (Reuters) - Brooks Laboratories Ltd BROO.NS:
TO CONSIDER AND APPROVE FUND RAISING THROUGH RIGHTS ISSUE
Source text for Eikon: ID:nBSE2xgtyB
Further company coverage: BROO.NS
(([email protected];))
Brooks Laboratories Fixes 115.8 Million Rupees As Right Issue Size
July 18 (Reuters) - Brooks Laboratories Ltd BROO.NS:
FIXED 115.8 MILLION RUPEES AS RIGHT ISSUE SIZE
RIGHT ISSUE PRICE AT 75 RUPEES PER SHARE
Source text for Eikon: ID:nBSE5SBQDR
Further company coverage: BROO.NS
(([email protected];))
July 18 (Reuters) - Brooks Laboratories Ltd BROO.NS:
FIXED 115.8 MILLION RUPEES AS RIGHT ISSUE SIZE
RIGHT ISSUE PRICE AT 75 RUPEES PER SHARE
Source text for Eikon: ID:nBSE5SBQDR
Further company coverage: BROO.NS
(([email protected];))
Events:
Rights
Rights
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Brooks Laboratories do?
Brooks Laboratories Limited focuses on critical care products including Beta Lactam, Cephalosporin, and General Dry powder Injectables. It provides a diverse product portfolio for multiple companies.
Who are the competitors of Brooks Laboratories?
Brooks Laboratories major competitors are Lyka Labs, Trident Lifeline, Zim Laboratories, Vaidya Sane Ayur Lab, Gennex Lab, Ambalal Sarabhai Ent, Balaxi Pharma.. Market Cap of Brooks Laboratories is ₹327 Crs. While the median market cap of its peers are ₹336 Crs.
Is Brooks Laboratories financially stable compared to its competitors?
Brooks Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Brooks Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Brooks Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Brooks Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Brooks Laboratories balance sheet?
Balance sheet of Brooks Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Brooks Laboratories improving?
Yes, profit is increasing. The profit of Brooks Laboratories is ₹5.64 Crs for TTM, -₹9.97 Crs for Mar 2025 and -₹19.59 Crs for Mar 2024.
Is the debt of Brooks Laboratories increasing or decreasing?
The net debt of Brooks Laboratories is decreasing. Latest net debt of Brooks Laboratories is ₹3.58 Crs as of Mar-25. This is less than Mar-24 when it was ₹3.68 Crs.
Is Brooks Laboratories stock expensive?
Brooks Laboratories is not expensive. Latest PE of Brooks Laboratories is 0.0, while 3 year average PE is 0.5. Also latest EV/EBITDA of Brooks Laboratories is 41.31 while 3yr average is 82.4.
Has the share price of Brooks Laboratories grown faster than its competition?
Brooks Laboratories has given lower returns compared to its competitors. Brooks Laboratories has grown at ~2.14% over the last 3yrs while peers have grown at a median rate of 3.08%
Is the promoter bullish about Brooks Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Brooks Laboratories is 52.62% and last quarter promoter holding is 52.62%.
Are mutual funds buying/selling Brooks Laboratories?
The mutual fund holding of Brooks Laboratories is stable. The current mutual fund holding in Brooks Laboratories is 9.9% while previous quarter holding is 9.9%.
